Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alkem Sees Domestic Recovery And International Growth

As Company Receives 10 ANDA Approvals In Financial Third Quarter

Executive Summary

India’s Alkem has announced growing domestically in its financial third quarter, after seeing a low first quarter due to COVID-19. The company has also reported progress in the international market, after receiving 10 ANDA approvals from the US FDA in Q3 FY21.

You may also be interested in...



Alkem Looks To Biosimilars With Enzene’s Teriparatide In India

With the approval in India of its Enzene subsidiary’s version of teriparatide, Alkem is setting its sights on the biosimilars market.

Biosimilar Education And Innovation Bills Head To Biden’s Desk

The Advancing Education on Biosimilars Act and the Ensuring Innovation Act will be looked at by the US President Joe Biden, after receiving the approval of both the Senate and the House of Representatives. The bills are aimed at lowering prescription drug costs and saving overall healthcare costs. 

Aurobindo’s Latest Launches Include Truvada And Atripla Rivals

Aurobindo has announced the launch of generic versions of Truvada, Atripla, Minocin and Gleevec in the US. As its generics business grows in the US, Europe, Canada and the rest of the world markets, Aurobindo plans to establish itself in China. The Indian pharma company has also announced its plan to commission new facilities to serve the external market. 

Topics

Related Companies

UsernamePublicRestriction

Register

GB150658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel